ABOUT
Overview
Management
Drug Development Team
Board of Directors
Corporate Partnerships
SCIENCE
Technology Platform
Scientific Publications
PIPELINE
Overview
Piclidenoson (CF101)
Namodenoson (CF102)
CF602
Cannabinoids
INVESTORS
Overview
News & Events
Company Information
Financial Information
Stock Information
SEC Fillings
Corporate Governance
Shareholders Meetings
CONTACT
Menu
×
Scientific Publications
HOME
Scientific Publications
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy and Safety of Namodenoson (CF102), an A3 Adenosine Receptor Agonist (A3AR)
Back